In vitrogrowth in acute myeloblastic leukaemia: relationship with other clinico-biological characteristics of the disease
- 1 October 1998
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 103 (1) , 137-142
- https://doi.org/10.1046/j.1365-2141.1998.00962.x
Abstract
The in vitro growth characteristics of a large series of acute myeloid leukaemia (AML) patients and their relationship with other clinical and biological disease characteristics were analysed. Patients with AML were studied, 181 with de novo AML and 45 with secondary AML (24 myelodysplastic syndrome, sAML-MDS, 21 myeloproliferative disorder, sAML-MPD). Leukaemic colony forming units (L-CFU) were assayed by plating peripheral blood (PB) blast cells in methyl-cellulose and using LCM-PHA as stimulant. In each case parallel cultures were made with and without stimulating factors. Plating efficiency (PE) was defined as the number of clusters plus colonies/105 cells plated. Autonomous growth (AG) was the number of colonies plus clusters growing without stimulant. The autonomous proliferative index (API) was calculated as the number of clusters + colonies without stimulating factor divided by the number of clusters + colonies with stimulating factor. No significant differences in the PE between de novo and secondary AML were found. Autonomous growth was significantly higher in sAML-MPD. The FAB subtype M3 leukaemias displayed a significantly greater PE and a significantly lower API when compared with the other FAB subgroups (P = 0.0002). Upon analysing the relationship with the immunophenotype, only CD33 expression showed a significant relationship with the in vitro growth pattern; CD33+ cases displayed a higher PE (P = 0.0002) and AG (P = 0.0003) than CD33− cases. When patients were grouped according to the level of rh123 efflux (MDR1) it was observed that cases with >30% elimination showed a higher AG and API than those with 0.05) displayed a significantly shorter overall survival as compared with patients with API < 0.05 (P = 0.04). The in vitro study properties of clonogenic cells produces relevant clinical information of leukaemic cell biology in AML patients.Keywords
This publication has 20 references indexed in Scilit:
- In vitro autonomous proliferation in ANLL: Clinical and biological significanceLeukemia Research, 1995
- Relationship between responsiveness to colony stimulating factors (CSFs) and surface phenotype of leukemic blastsLeukemia Research, 1995
- Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implicationsThe Lancet, 1994
- The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AMLAnnals of Hematology, 1994
- Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kineticsAnnals of Hematology, 1993
- Surface marker analysis in acute myeloid leukaemia and correlation with FAB classificationBritish Journal of Haematology, 1986
- Proposed Revised Criteria for the Classification of Acute Myeloid LeukemiaAnnals of Internal Medicine, 1985
- The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemiaAmerican Journal of Hematology, 1983
- In vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: growth pattern and drug sensitivityBritish Journal of Haematology, 1983
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976